← All Equillium, INC filings

Equillium, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
EQ
Equillium, INC
10-K: Equillium Secures $35M, Advances EQ504 to Phase 1
Equillium, a biotechnology company, reported significant losses for 2025 but secured $35 million in March 2026 to fund the advancement of its lead candidate, EQ504, into Phase 1 clinical trials by mid-2026.
NASDAQ
EQ
Equillium, INC
10-K: Equillium, Inc. Reports Disappointing Phase 3 Results for Itolizumab in aGVHD, Faces Going Concern Uncertainty
Equillium's Phase 3 EQUATOR study of itolizumab in acute graft-versus-host disease (aGVHD) failed to meet primary endpoints, raising concerns about the company's future and ability to continue as a going concern.
NASDAQ
EQ
Equillium, INC
10-K: Equillium, Inc. Files 10-K Report Detailing Clinical Programs and Financials
Equillium, Inc. released its 10-K filing, outlining its clinical development programs for EQ101, EQ302, and itolizumab (EQ001), along with its financial status.